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Purpose: A number of potential determinants of medication non-adherence have been
described so far. However, the heterogenic quality of existing publications poses the
need for the use of a rigorous methodology in building a list of such determinants. The
purpose of this study was a systematic review of current research on determinants of
patient adherence on the basis of a recently agreed European consensus taxonomy and
terminology.
Methods: MEDLINE, EMBASE, CINAHL, Cochrane Library, IPA, and PsycINFO were
systematically searched for systematic reviews published between 2000/01/01 and
2009/12/31 that provided determinants on non-adherence to medication. The searches
were limited to reviews having adherence to medication prescribed by health professionals
for outpatient as a major topic.
Results: Fifty-one reviews were included in this review, covering 19 different disease
categories. In these reviews, exclusively assessing non-adherence to chronic therapies,
771 individual factor items were identified, of which most were determinants of
implementation, and only 47—determinants of persistence with medication. Factors
with an unambiguous effect on adherence were further grouped into 8 clusters of
socio-economic-related factors, 6 of healthcare team- and system-related factors, 6 of
condition-related factors, 6 of therapy-related factors, and 14 of patient-related factors.
The lack of standardized definitions and use of poor measurement methods resulted in
many inconsistencies.
Conclusions: This study provides clear evidence that medication non-adherence is
affected by multiple determinants. Therefore, the prediction of non-adherence of individual
patients is difficult, and suitable measurement and multifaceted interventions may be
the most effective answer toward unsatisfactory adherence. The limited number of
publications assessing determinants of persistence with medication, and lack of those
providing determinants of adherence to short-term treatment identify areas for future
research.
Keywords: medication adherence, patient compliance, persistence, concordance, medication use, determinants of
adherence
INTRODUCTION
Enormous progress in the fields of both medicine, and pharma-
cology has taken place in the last century and led to a completely
new paradigm of treatment. Contrary to the past, in which most
treatments were only available in hospitals, effective remedies are
available now in ambulatory settings. At the same time, the demo-
graphic changes that happen to both developed and developing
countries, make chronic conditions even more prevalent. All this
makes the most modern treatments dependent on patient self-
management. Surprisingly often, evidence based treatments fail
to succeed because of the human factor known for a few decades
as patient non-adherence.
Currently, sound theoretical foundations for adherence-
enhancing interventions are lacking (van Dulmen et al., 2007).
Therefore, the development of interventions to enhance patient
adherence to medication, and maintain long term persistence,
requires at least an understanding of the determinants of patient
non-adherence to prescribed therapies. This is especially impor-
tant when the determinants are modifiable risk factors, which,
once identified, can then be targeted for beneficial changes.
The published literature identifies hundreds of determi-
nants of non-adherence. Unfortunately, serious drawbacks of
the methodology used by numerous studies demand that this
list be revised. In particular, many studies do not indicate the
relative importance of the 3 identified components of patient
adherence: initiation, implementation, and discontinuation. For
example, the WHO recommends that determinants be classi-
fied in 5 dimensions (Sabate, 2003): socio-economic factors,
healthcare team and system-related factors, condition-related
factors, therapy-related factors, and patient-related factors, but
provides little or no closure in respect to outcome, and in
particular, to the stage of adherence process. Moreover, little
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information exists on the determinants of short-term adher-
ence for acute diseases vs. long-term adherence for chronic
diseases.
The objective of this study was to identify and classify the
determinants of non-adherence to short-term and long-term
treatments for different clinical sectors and population segments.
In order to obtain this goal, a retrospective systematic review
of the literature was performed, wherein we have adopted the
method of reviewing reviews. In order to design a comprehen-
sive, yet evidence-based list of determinants of patient adherence
for use in both practical and clinical settings, as well as for theo-
retical purposes to inform adherence-enhancing interventions, a
rigorous taxonomy and terminology of adherence was used, the
basis of which was set recently in a form of a European consensus
(Vrijens et al., 2012). According to this terminology, adherence to
medications is defined as the process by which patients take their
medications as prescribed. Adherence has three components: ini-
tiation, implementation, and discontinuation, of which initiation is
defined as themoment at which the patient takes the first dose of a
prescribedmedication; the implementation of the dosing regimen,
being the extent to which a patient’s actual dosing corresponds to
the prescribed dosing regimen from initiation until the last dose
taken; and discontinuation, being the end of therapy, when the
next dose to be taken is omitted and no more doses are taken
thereafter (Vrijens et al., 2012).
This study is part of a larger project on patient medica-
tion adherence funded by the European Commission called the
“ABC (Ascertaining Barriers for Compliance) Project” (http://
www.abcproject.eu). The overall goal of the ABC project was
to produce evidence-based policy recommendations for improv-
ing patient adherence and by so doing to promote safer, more
effective and cost-effective medicines use in Europe.
FIGURE 1 | Flow diagram of study selection process.
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METHODS
As the number of publications with the keyword “patient com-
pliance” (text word), and “patient compliance” as MESH major
term is so high, (close to 50,000 hits, and 16,000 in PubMed
by 2009/12/31, respectively), only recent systematic reviews are
included in this search; More precisely the inclusion criteria
comprised systematic reviews in the English language, published
between 2000/01/01 and 2009/12/31, having adherence to medi-
cation intended to be taken in outpatient settings prescribed by
health professionals, as a major topic of publication, if determi-
nants of adherence are provided.
MEDLINE (through PubMed), EMBASE, CINAHL, the
Cochrane Library, International Pharmaceutical Abstracts (IPA),
and PsycINFOwere searched for relevant publications. In order to
increase search coverage, a number of possible synonyms formed-
ication adherence (i.e., patient compliance, concordance, patient
dropouts, treatment refusal, and directly observed therapy), in com-
bination with several synonyms of determinants were used for
keywords. The detailed search strategies for all databases are pro-
vided in Appendix 1. For the other databases, the search strategies
were adapted accordingly.
Papers were excluded for the following reasons: (1) Studies
that primarily focused on adherence-enhancing interventions. (2)
Studies that were not systematic reviews. (3) Studies that assessed
adherence to non-medication intervention (e.g., vaccination). (4)
Double citations. (5) Determinants of adherence to medication
not provided. No paper was excluded on the grounds of quality.
Eligibility assessment of title and abstract was performed inde-
pendently in an unblended standardizedmanner by two reviewers
(PK, PL). If at least one reviewer coded a review as potentially eli-
gible, the review was included for full-text review. The full texts of
potentially eligible reviews were retrieved and reviewed by both
reviewers. Disagreements were resolved by discussion and a final
decision was reached between the two reviewers.
A structured data collection sheet was developed to extract
data from each review. All available relevant data was extracted
from the reviews; no additional information was sought from
the authors. The following paragraphs describe which data was
extracted.
DETERMINANTS OF ADHERENCE TO MEDICATION
A range of determinants were extracted based on the source pub-
lications. These were further categorized according to their effect
on adherence to medication using an adherence determinant
matrix. Relevant dimensions included:
• Treatment duration: long- vs. short-term treatment;
• Components of adherence to medication: implementation of the
dosing regimen (defined as the extent to which a patient’s
actual dosing corresponds to the prescribed dosing regimen)
vs. persistence (defined as the length of time between initiation
and the last dose which immediately precedes discontinua-
tion) (Vrijens et al., 2012). Determinants were categorized
under implementation unless original review wording clearly
addressed persistence.
• Dimensions of adherence: these were socio-economic factors,
healthcare team- and system-related factors, condition-related
factors, therapy-related factors, and patient-related factors. In
this was original WHO report description followed (Sabate,
2003), with a modification: demographic variables were
included under patient-related, instead of socio-economic
related factors.
• Direction of effect: determinants were classified according to
their positive, negative, neutral, or not defined effect on adher-
ence.
Other data extracted from the reviews included scope of the
review (medical condition, class of drugs, etc.), studied popula-
tion, and databases searched by the authors.
RESULTS
In this systematic literature review, 51 systematic reviews were
found to contain determinants of adherence to medication. An
overview of the review process and reasons for exclusion at var-
ious steps within it are detailed in Figure 1. Individual study
characteristics are listed in Appendix 2. Great variety was seen in
both the start year of the literature searches performed within the
source reviews, starting back from as early as 1948, or as late as
2000, as well as the period covered by the search, varying from 5
to over 50 years. Most of the studies accepted broad definitions
Table 1 | Fields covered by the selected reviews.
Field No. of reviews
Miscellaneous diseases 10
HIV 8
Psychiatric conditions 8
Diabetes 3
Hypertension 3
Cancer 2
End stage renal disease 2
Multiple sclerosis 2
Osteoporosis 2
Transplantations 2
Tuberculosis 2
Cystic fibrosis 1
Skin diseases 1
Glaucoma 1
Heart failure 1
Malaria 1
Opioid dependence 1
Non-malignant chronic pain 1
Table 2 | Patient groups covered by the selected reviews.
Patient group No.
Not specified 25
Adults 11
Children + adults 8
Children 4
Elderly 2
Youth 1
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Table 3 | Socio-economic factors affecting adherence.
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
FAMILY SUPPORT
Lack of family support (Nosé et al., 2003; Munro et al., 2007;
Costello et al., 2008)
Irregular supervision by a family member (Munro et al.,
2007P)
Child selfresponsibility for taking medication (Kahana et al.,
2008)
Family financial support (Munro et al.,
2007; Lanouette et al., 2009)
Family support in executing medication
(Oehl et al., 2000; Munro et al., 2007;
Lanouette et al., 2009)
Family emotional support (Weiner
et al., 2008; Lanouette et al., 2009)
Family involvement during
hospitalization or follow-up (Lacro
et al., 2002)
FAMILY/CAREGIVERS FACTORS
Disorganized biologic families (Kahana et al., 2008;
Karamanidou et al., 2008; Vreeman et al., 2008)
Family in conflict (Oehl et al., 2000; DiMatteo, 2004a;
Vreeman et al., 2008; Weiner et al., 2008)
Responsibilities in the home (such as providing income and
caring for children) (Munro et al., 2007)
Low parental educational level (Vreeman et al., 2008)
Family beliefs about the nature of the patient’s illness (Julius
et al., 2009)
More people in household (in children) (DiMatteo, 2004a)
Having several adults involved in pill supervision (Vreeman
et al., 2008)
Two-parent families (Charach and Gajaria,
2008P)
Family cohesiveness (DiMatteo, 2004a)
Having an adult other than the biologic
parent as primary caregiver (Reisner et al.,
2009)
Higher caregiver education level (Reisner
et al., 2009)
Responsibilities in the family (Munro et al.,
2007)
Parental belief that ADHD is a biological
condition (Charach and Gajaria, 2008P)
Mother’s perception of the severity of
disease (Hodari et al., 2006)
Knowledge of family members
regarding disease (Lacro et al., 2002)
Family member with mental illness
(Lanouette et al., 2009)
Number of people in the household
(Vermeire et al., 2001)
Parental marital status (Charach and
Gajaria, 2008P)
SOCIAL SUPPORT
Lack of social support (Oehl et al., 2000; Fogarty et al., 2002;
DiMatteo, 2004a; Mills et al., 2006; Costello et al., 2008;
Hirsch-Moverman et al., 2008; Karamanidou et al., 2008;
Malta et al., 2008; Weiner et al., 2008; Julius et al., 2009;
Schmid et al., 2009)
Less acculturation (Lanouette et al., 2009)
Low social functioning (Nosé et al., 2003)
Low social rank of an illness (Oehl et al., 2000)
Negative publicity regarding HAART or the medical
establishment (Mills et al., 2006)
Emotional support (DiMatteo, 2004a)
Good social adjustment (Pampallona et al.,
2002; Nosé et al., 2003)
Including significant others into therapeutic
alliance (Oehl et al., 2000)
Supervision of medication administration
by others (Weiner et al., 2008; Julius et al.,
2009)
Patients’ support to patients (Munro et al.,
2007; Costello et al., 2008)
Social support (Reisner et al., 2009)
SOCIAL STIGMA OF A DISEASE
Stigma of a disease at school, at workplace, among the
family and friends (Munro et al., 2007; Vreeman et al., 2008;
Reisner et al., 2009)
Negative attitude in the patient’s social surroundings toward
psychiatric treatment (Oehl et al., 2000)
Fear of disclosure and wanting to avoid taking medications in
public places (Mills et al., 2006)
Disclosure of the child’s HIV status (Vreeman et al., 2008)
Hiding the disease (TB) for fear that employers may discover
it (Munro et al., 2007)
Openly disclosing HIV status to family and
friends (Mills et al., 2006)
COSTS OF DRUGS AND/OR TREATMENT
Cost of drugs (co-payment) (Vermeire et al., 2001; Gold et al.,
2006P; Hodari et al., 2006; Lewiecki, 2007; Vreeman et al.,
2008; Schmid et al., 2009)
Costs of drugs and treatment (Munro et al., 2007P; Costello
et al., 2008P)
PRESCRIPTION COVERAGE
Lack of, or inadequate medical/prescription coverage
(Charach and Gajaria, 2008P; Costello et al., 2008P; Lanouette
et al., 2009; Schmid et al., 2009)
Fear of asking for money from employer to purchase drugs (in
TB) (Munro et al., 2007)
Having health insurance (Lanouette et al.,
2009)
(Continued)
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Table 3 | Continued
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
SOCIOECONOMIC STATUS
Low income (Jindal et al., 2003; DiMatteo, 2004b; Munro
et al., 2007; Schmid et al., 2009)
Poverty (Munro et al., 2007P; Costello et al., 2008P; Vreeman
et al., 2008)
Lower socioeconomic status (DiMatteo, 2004b; Charach and
Gajaria, 2008P; Lanouette et al., 2009)
Financial constraints (Oehl et al., 2000; Mills et al., 2006)
Wanting to remain sick to qualify for financial support (Munro
et al., 2007)
Socioeconomic status (Vermeire et al.,
2001; Munro et al., 2007; Charach and
Gajaria, 2008P; Karamanidou et al.,
2008; Weiner et al., 2008; Ruddy et al.,
2009)
Financial support from outside the
family (Lanouette et al., 2009)
EMPLOYMENT STATUS
Unemployment (Nosé et al., 2003; Hodari et al., 2006)
White-collar employment (Jindal et al., 2003)
Employment status (Karamanidou
et al., 2008)
Abbreviations: TB, tuberculosis; P , determinant of persistence.
of adherence, making no distinction between intentional, and
unintentional non-adherence; only in 4 studies were clear oper-
ational definitions provided (Iskedjian et al., 2002; Lacro et al.,
2002; Wetzels et al., 2004; Bao et al., 2009; Parienti et al., 2009).
The majority of the studies were systematic reviews. However,
8 reviews (DiMatteo et al., 2000, 2007; Iskedjian et al., 2002;
DiMatteo, 2004a,b; Gonzalez et al., 2008; Bao et al., 2009; Parienti
et al., 2009) were also enriched with meta-analyses, and provided
calculations of the effect on adherence of factors from several
dimensions:
• Socio-economic factors: practical social support (OR 3.60,
95%CI 2.55 - 5.19), emotional support (OR 1.83, 95%CI 1.27,
2.66], unidimensional social support (OR 2.35, 95%CI 1.76–
3.03], family cohesiveness (OR 3.03, 95%CI 1.99–4.52], being
married (OR 1.27, 95%CI 1.12–1.43), as well as living with
someone (for adults, OR 1.38, 95%CI 1.04–1.83) increased
the odds of adherence, whereas family conflict decreased these
odds (OR 2.35, 95%CI 1.08, 5.71) (DiMatteo, 2004a)
• Condition-related factors: patients rated poorer in health by
their physicians were more adherent to treatment (OR 1.76,
95%CI 1.13 - 2.77) (DiMatteo et al., 2007)
• Therapy-related factors: the average adherence rate for QD
dosing was significantly higher than for BID dosing in hyper-
tension (92.7% vs. 87.1%) (Iskedjian et al., 2002) and antiretro-
viral therapy (+2.9%, 95%CI 1.0-4.8%) (Parienti et al., 2009),
in hypertension adherence was also significantly higher for
QD dosing vs. >QD dosing (91.4 vs. 83.2%, respectively)
(Iskedjian et al., 2002). In methadone treatment, persistence
was higher with higher daily methadone doses (> or =60mg
vs. <60mg/day, OR: 1.74, 95%CI 1.43-2.11), as well as with
flexible-dose strategies vs. fixed-dose strategies (OR: 1.72,
95%CI 1.41–2.11) (Bao et al., 2009)
• Patient-related factors: an extensive review found older age,
female gender, higher income, and more education to have
small yet positive effects on adherence (DiMatteo, 2004b). A
belief that the medical condition in question was a threat
because of its severity increased the odds of adherence (OR
2.45, 95%CI 1.91–3.16) (DiMatteo et al., 2007). Depression
was significantly associated with non-adherence across vari-
ous conditions (OR 3.03, 95%CI 1.96–4.89) (DiMatteo et al.,
2000), and in particular, in diabetes (z 9.97, P 0.0001)
(Gonzalez et al., 2008).
Within our selected reviews, the most common focus of the stud-
ies were miscellaneous diseases (10 reviews) (DiMatteo et al.,
2000, 2007; Claxton et al., 2001; Vermeire et al., 2001; Connor
et al., 2004; DiMatteo, 2004a,b; Vik et al., 2004; Chia et al., 2006;
Kruk and Schwalbe, 2006), followed by HIV (8 reviews) (Fogarty
et al., 2002; Mills et al., 2006; Malta et al., 2008; Vreeman et al.,
2008; Lovejoy and Suhr, 2009; Parienti et al., 2009; Ramos, 2009;
Reisner et al., 2009), and psychiatric conditions (8 reviews) (Oehl
et al., 2000; Lacro et al., 2002; Pampallona et al., 2002; Nosé
et al., 2003; Santarlasci and Messori, 2003; Charach and Gajaria,
2008; Julius et al., 2009; Lanouette et al., 2009) (Table 1). Disease
categories were broad (19 different diseases); reviews exclusively
reported patients with chronic diseases.
Close to half of the reviews (25 out of 51) did not specify the
age group of patients covered by the review. Of the rest, most dealt
with adults (11 reviews, Table 2).
DETERMINANTS OF ADHERENCE TO MEDICATION
As many as 771 individual factor items associated with long-term
treatment were extracted from the reviewed literature: Despite
the broad range of the fields covered with these publications,
no publication primarily focusing on short-term therapies was
identified, nor were any individual determinants of patient adher-
ence to short-term treatment. The vast majority of individual
factor items were determinants of implementation, and only 47
were found to be determinants of persistence with medication.
Only three reviews addressed the initiation component of adher-
ence, although no corresponding determinants were provided
(Vermeire et al., 2001; Vik et al., 2004; Costello et al., 2008).
For 64 individual factor items, no unambiguous informa-
tion concerning their effect on adherence to medication could
be found in the source publication. The remaining factors were
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Table 4 | Healthcare team and system-related factors affecting adherence.
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
BARRIERS TO HEALTHCARE
Barriers to high-quality care (Lanouette et al., 2009)
Lack of providers/caregiver availability (Charach and Gajaria,
2008P; Vreeman et al., 2008)
Rural settings (Vreeman et al., 2008)
Poor access to a health care facility (e.g., long waiting times,
queues, lack of privacy, inconvenient appointment times,
inconvenient opening hours) (Munro et al., 2007)
Seeing different language speaking therapist (ie
Spanish-speaking therapist in US Latinos) (Lanouette et al.,
2009)
Difficulty in obtaining sick leave for treatment (Munro et al.,
2007)
Having no time to refill prescriptions, or other
pharmacy-related problems (Mills et al., 2006)
Good access to medication and health
service (Fogarty et al., 2002)
Good access to a health care facility (Nosé
et al., 2003; Munro et al., 2007)
Non-emergency referral (Pampallona et al.,
2002)
Obtaining certification of preventive
treatment (for immigrants to US) (Munro
et al., 2007)
Access to care (Lacro et al., 2002)
Greater distance from the clinic (Jindal
et al., 2003; Munro et al., 2007)
Current inpatient status (Lacro et al.,
2002)
Rural settings (vs. urban) (Lacro et al.,
2002)
Type of transportation used (Lacro
et al., 2002)
DRUG SUPPLY
Poor drug supply (e.g., poor TB medication availability at
health care facilities) (Mills et al., 2006; Munro et al., 2007)
Unavailability of medications (e.g., prescription ran out) (Vik
et al., 2004)
Receiving treatment together with
methadone from a street nurse (for DOT in
TB, in IDU patients) (Munro et al., 2007)
PRESCRIPTION BY A SPECIALIST
Referral/prescription by a specialist
(Pampallona et al., 2002; Van Der Wal et al.,
2005)
Prescription by a psychiatrist (in
depression) (Lanouette et al., 2009)
INFORMATION ABOUT DRUG ADMINISTRATION
Unclear information about proper drug administration (Vik
et al., 2004)
Greater number of prescribing physicians (Vik et al., 2004)
Conflicting messages between gps and specialists on
medication (Hodari et al., 2006)
Discrepancies between treatment guidelines and common
clinical practice (as patients try to ask several specialists)
(Oehl et al., 2000)
Use of multiple pharmacies (Vik et al., 2004)
Doctor’s ability to provide appropriate
information as to the drug administration
(Vermeire et al., 2001; Weiner et al., 2008)
Being given information about the action of
the drugs (Olthoff et al., 2005)
HEALTHCARE PROVIDER-PATIENT COMMUNICATION AND RELATIONSHIP
Poor healthcare provider-patient relationship (Oehl et al.,
2000; Vermeire et al., 2001; Lacro et al., 2002; Nosé et al.,
2003; Vik et al., 2004; Olthoff et al., 2005; Hodari et al., 2006;
Munro et al., 2007; Charach and Gajaria, 2008P; Costello
et al., 2008; Broekmans et al., 2009; Julius et al., 2009)
Poor patient–physician communication (Vermeire et al., 2001;
Gold et al., 2006P; Hodari et al., 2006; Munro et al., 2007;
Broekmans et al., 2009; Jacobsen et al., 2009; Julius et al.,
2009)
Lack of trust in doctors and healthcare (Chia et al., 2006;
Mills et al., 2006; Broekmans et al., 2009)
Lack of patient satisfaction with their healthcare, (Hodari
et al., 2006; Mills et al., 2006)
Limited caregiver adherence strategies (Vreeman et al., 2008)
Quality, duration and frequency of
interaction between the patient and doctor
(Vermeire et al., 2001)
Offering enough time to the patient,
leaving space to talk about problems
concerning medication or side effects (Oehl
et al., 2000)
Patient involvement in decision making
(Gold et al., 2006P; Mills et al., 2006;
Ruddy et al., 2009)
Encouraging self-management (Weiner
et al., 2008)
Doctor responsiveness (Vermeire et al.,
2001)
Doctor’s ability to demonstrate empathy
(Vermeire et al., 2001)
Doctor’s ability to elicit and respect the
patient’s concerns (Vermeire et al., 2001)
Perceived healthcare provider support
(Fogarty et al., 2002; Costello et al., 2008)
(Continued)
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Table 4 | Continued
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
FOLLOW-UP
Inadequate discharge planning (Julius et al., 2009; Lacro
et al., 2002)
Fewer outpatient visits (Vik et al., 2004; Olthoff et al., 2005;
Van Der Wal et al., 2005; Broekmans et al., 2009; Julius
et al., 2009)
Poor follow-up by providers (Lacro et al., 2002; Gold et al.,
2006P; Munro et al., 2007; Reisner et al., 2009)
More visits to a nonmedical therapist
(Lanouette et al., 2009)
Seeing a greater number of physicians
(Ruddy et al., 2009)
Clinic attendance (Jindal et al., 2003)
Abbreviations: GP, general practitioner; TB, tuberculosis; P , determinant of persistence.
grouped to form 400 individual determinants: 143 with a posi-
tive, 155 with negative, and 102 with neutral effect on adherence.
In cases where the source publications provided two “mirror” ver-
sions of the same factor, e.g., family support and lack of family
support„ these were recategorized as the factor with a negative
effect on adherence, in this case, lack of family support. The
determinants were further clustered according to the modified
WHO 5 dimension of adherence (see Methods for details). The
results are presented in Tables 3–7 as socio-economic-related
factors (8 clusters), healthcare team- and system-related factors
(6 clusters), condition-related factors (6 clusters), therapy-related
factors (6 clusters), and patient-related factors (14 clusters).
DISCUSSION
In this systematic literature review, 51 systematic reviews con-
cerning the determinants of adherence of medication were iden-
tified. Remarkably, a vast majority of the reviewed literature
provided only determinants of implementation. In fact, many
reviews lacked a clear definition of adherence, thus leaving the
distinction between implementation and persistence open to
interpretation. In the present study, these cases were arbitrar-
ily reclassified under determinants of implementation, assuming
that in most cases, authors were interested in the day-to-day
execution of drug taking. The recently-agreed European con-
sensus on taxonomy and terminology of adherence has made
more precise reporting of research findings in the field of adher-
ence to medication possible (Vrijens et al., 2012). However, in
interpreting results of this study, one has to have in mind this
limitation.
Many reviews reported a positive effect of family and social
support on implementation, and a negative effect of the lack
of such support (Table 3). The social stigma of a disease may
also be responsible for non-adherence in a number of cases.
Finally, economic factors such as unemployment, poverty, lack
of, or inadequate medical/prescription coverage, as well as a
high out-of-pocket cost of drugs may seriously contribute to
non-adherence.
Although non-adherence has often been perceived as the fault
of patients, and not of healthcare providers, there is evidence that
healthcare system factors have an important impact on adherence
(Table 4). Poor access to healthcare, poor drug supply, unclear
information about drug administration, as well as poor follow-up
and poor provider-patient communication and relationship may
reduce the extent to which patients follow the treatment plan.
Adherence is also related to condition. Asymptomatic nature
of the disease, as well as clinical improvement reduce patient
motivation to take the drugs as prescribed, whereas disease sever-
ity has a positive effect on adherence (Table 5). Patients are also
less happy to take the prescribed medication properly in both
chronic and psychiatric conditions.
If treatment is patient unfriendly – e.g., due to frequent dos-
ing, high number of prescribed medications, longer duration
of treatment, drug formulation or taste of low acceptance, or
the presence of adverse effects, the likelihood of patient adher-
ence drops (Table 6). Certain drug classes are better adhered to
compared with others.
Not surprisingly, many patient-related factors were found to
be reported as having an inconsistent impact on adherence in
terms of implementation (Table 7). This was particularly true for
demographic factors: whereas younger age was reported to have a
negative impact on adherence, and older age a positive one, many
reviews found no relationship between age and implementation
of treatment regimen (Oehl et al., 2000; Vermeire et al., 2001;
Lacro et al., 2002; DiMatteo, 2004b; Vik et al., 2004; Olthoff et al.,
2005; Hodari et al., 2006; Hirsch-Moverman et al., 2008; Reisner
et al., 2009; Ruddy et al., 2009). The male gender was reported
to have a negative impact in some reviews (Nosé et al., 2003;
Olthoff et al., 2005; Schmid et al., 2009), and the female gender
a positive one (Oehl et al., 2000; Pampallona et al., 2002; Chia
et al., 2006; Munro et al., 2007; Julius et al., 2009). However, gen-
der was found irrelevant for adherence in many cases (Vermeire
et al., 2001; Fogarty et al., 2002; Lacro et al., 2002; DiMatteo,
2004b; Vik et al., 2004; Van Der Wal et al., 2005; Charach and
Gajaria, 2008; Hirsch-Moverman et al., 2008; Karamanidou et al.,
2008; Broekmans et al., 2009; Lanouette et al., 2009; Reisner et al.,
2009), and male gender was found to have a contrary effect with
posttransplant medications (Charach andGajaria, 2008) andwith
psychostymulants in children with ADHD (Jindal et al., 2003).
The same was true for marital status, with some reviews indicat-
ing that those married tended to have better adherence than those
being single or divorced, education level, with better adherence
demonstrated by patients with higher levels of education, and
ethnicity, with higher adherence in Caucasians. Patient attitudes
and believes in favor of diagnosis, health recommendations and
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Table 5 | Condition-related factors affecting adherence.
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
PRESENCE OF SYMPTOMS
Asymptomatic nature of the disease or absence of
symptoms (Vermeire et al., 2001; Olthoff et al., 2005; Gold
et al., 2006P; Costello et al., 2008)
Increased severity and number of
symptom (Nosé et al., 2003; Munro et al.,
2007; Charach and Gajaria, 2008P; Brandes
et al., 2009; Lanouette et al., 2009)
Disability (Vermeire et al., 2001; Costello
et al., 2008)
Pain duration (Broekmans et al., 2009)
Pain intensity (Broekmans et al., 2009)
Presence of tremor (Jindal et al.,
2003)
DISEASE SEVERITY
Lower affective pain ratings (Broekmans et al., 2009)
Detectable viral load (in HIV-infected youth) (Reisner et al.,
2009)
Disease severity (Van Der Wal et al., 2005;
DiMatteo et al., 2007; Reisner et al., 2009;
Ruddy et al., 2009)
Perceptions of disease severity (DiMatteo
et al., 2007)
More hospitalization (before starting ART in
children) (Vreeman et al., 2008)
Disease severity (Cramer, 2004;
DiMatteo, 2004b; Chia et al., 2006;
DiMatteo et al., 2007; Weiner et al.,
2008; Julius et al., 2009; Lanouette
et al., 2009)
Worse clinical status (Fogarty et al.,
2002)
Possible consequences of missed
doses (Cramer, 2004)
CLINICAL IMPROVEMENT
Clinical improvement, disappearance of symptoms, feeling
better/cured (Oehl et al., 2000P; Mills et al., 2006; Munro
et al., 2007P; Ruddy et al., 2009)
Onset of clinical symptoms (in latent TB infection)
(Hirsch-Moverman et al., 2008)
Perception of a clinical improvement (Oehl
et al., 2000)
Reduced viral load (in HIV-infected youth)
(Reisner et al., 2009)
PSYCHIATRIC CONDITION
Psychiatric disorders (Vermeire et al., 2001; Nosé et al., 2003)
Negative symptoms/motivational deficits (Oehl et al., 2000)
Lower rates of narcissistic-histrionic
personality disorder (in depression)
(Pampallona et al., 2002)
Severity of psychotic symptoms
(Lacro et al., 2002)
CERTAIN DIAGNOSES/INDICATIONS
Certain diagnoses (pulmonary conditions, DM, and sleep
disorders vs. other) (DiMatteo, 2004b)
Indication (pain medication vs. other medications)
(Broekmans et al., 2009)
Certain diagnoses: rheumatoid arthritis vs.
other types of arthritis (Broekmans et al.,
2009), combined subtype in ADHD, vs.
inattentive or hyperactive subtype (Charach
and Gajaria, 2008P), disease group (HIV,
arthritis, GI diseases, and cancer vs. other)
(DiMatteo, 2004b), disease group
(diagnosis other than personality disorder
and substance abuse, in depression)
(Pampallona et al., 2002)
Estrogen receptor positive (in breast
cancer) (Ruddy et al., 2009)
Cause of ESRD (Karamanidou et al.,
2008)
Latent or active TB (Munro et al.,
2007)
Disease factors (Vermeire et al., 2001)
DURATION OF THE DISEASE
Chronic nature of the disease (Hodari et al., 2006)
Longer time since clinic visit (Olthoff et al., 2005)
Longer time since transplant (Jacobsen et al., 2009)
Later disease stage (in HIV-infected youth) (Reisner et al.,
2009)
Shorter duration of illness (in schizophrenia) (Lacro et al.,
2002)
Longer duration of pain (Chia et al., 2006) Duration of the disease (Lanouette
et al., 2009)
Length of time of hemodialysis
(Karamanidou et al., 2008; Schmid
et al., 2009)
Abbreviations: ART, antiretroviral therapy; ESRD, end stage renal disease; TB, tuberculosis; P , determinant of persistence.
self-efficacy were closely related to adherence, as was knowl-
edge of the disease and consequences of poor adherence. On the
other hand, many beliefs were found to be possible barriers for
strict adherence. Poorer adherence can be expected with either
drug or alcohol dependence. Finally, comorbidities and patient
history had an inconsistent effect on adherence, with the excep-
tion of psychiatric conditions, which was frequently reported to
be connected with the lower rates of adherence (Claxton et al.,
2001; Jindal et al., 2003; Nosé et al., 2003; Hodari et al., 2006;
Mills et al., 2006; Munro et al., 2007; Charach and Gajaria, 2008;
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Table 6 | Therapy-related factors affecting adherence.
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
ADVERSE EFFECTS
Adverse effects (Oehl et al., 2000; Vermeire et al., 2001;
Fogarty et al., 2002; Pampallona et al., 2002; Vik et al., 2004;
Chia et al., 2006; Gold et al., 2006P; Hodari et al., 2006; Mills
et al., 2006; Lewiecki, 2007; Munro et al., 2007; Charach and
Gajaria, 2008P; Costello et al., 2008P; Karamanidou et al.,
2008; Vreeman et al., 2008; Weiner et al., 2008; Brandes
et al., 2009P; Julius et al., 2009; Reisner et al., 2009; Schmid
et al., 2009)
Decreased quality of life while taking medications (Hodari
et al., 2006; Mills et al., 2006)
Adverse effects (Lacro et al., 2002;
Olthoff et al., 2005)
PATIENT FRIENDLINESS OF THE REGIMEN
Complexity of the regimen (e.g., complex/frequent dosing
schedule/number of tablets) (Oehl et al., 2000; Vermeire
et al., 2001; Fogarty et al., 2002; Van Der Wal et al., 2005;
Gold et al., 2006P; Mills et al., 2006; Munro et al., 2007P;
Vreeman et al., 2008; Weiner et al., 2008; Brandes et al.,
2009; Julius et al., 2009; Schmid et al., 2009)
Dosing frequency (Claxton et al., 2001; Vermeire et al., 2001;
Olthoff et al., 2005; Van Der Wal et al., 2005; Hodari et al.,
2006; Mills et al., 2006; Charach and Gajaria, 2008P;
Vreeman et al., 2008)
Number of prescribed medications (polymedication)
(Vermeire et al., 2001; Broekmans et al., 2009)
Less medication prescribed (in patients with chronic
non-malignant pain) (Broekmans et al., 2009)
Doses during day (particularly the middle-of-day or
early-morning doses) (Mills et al., 2006; Charach and Gajaria,
2008P)
Instability of the regimen (Van Der Wal et al., 2005)
Inconvenience associated with administration of some
medication (e.g., oral biphosphonates) (Olthoff et al., 2005;
Gold et al., 2006P; Hodari et al., 2006; Brandes et al., 2009)
Injection formulation (e.g., insulin) (Cramer, 2004; Munro
et al., 2007P; Costello et al., 2008; Brandes et al., 2009)
Need to adjust dietary habits for taking medication (Fogarty
et al., 2002; Hodari et al., 2006; Mills et al., 2006; Munro
et al., 2007; Vreeman et al., 2008)
Problems with opening containers (Vik et al., 2004)
Disliking aspects of the medication (Ruddy et al., 2009)
Poor taste of medication (Mills et al., 2006; Weiner et al.,
2008; Schmid et al., 2009)
Big tablet size, problems with swallowing tablets (Vik et al.,
2004; Mills et al., 2006; Weiner et al., 2008; Schmid et al.,
2009)
Once-daily dosing (vs. more frequent one)
(Iskedjian et al., 2002; Cramer, 2004;
Wetzels et al., 2004; Lee et al., 2006;
Parienti et al., 2009)
Once-weekly dosing (vs. once-daily) (Kruk
and Schwalbe, 2006)
Simple regimen (Mills et al., 2006)
Fewer drugs prescribed (Cramer, 2004;
Reisner et al., 2009)
Fixed-dose combination pills (Connor et al.,
2004; Yeung and White, 2005)
Long acting formulation (Charach and
Gajaria, 2008P)
Unit-of-use packaging (Connor et al., 2004)
Flexibility/patient choice in treatment
(Munro et al., 2007; Bao et al., 2009P)
Dosing through injections (Oehl et al.,
2000; Vermeire et al., 2001; Lewiecki,
2007; Schmid et al., 2009)
Regular medication schedule (vs. irregular
dose interval) (Van Der Wal et al., 2005)
Simplicity of regimen (Cramer, 2004)
Regimen complexity (Lacro et al.,
2002; Olthoff et al., 2005;
Karamanidou et al., 2008)
Number of prescribed medications
(Chia et al., 2006)
Once-monthly dosing (vs. once-daily)
(Kruk and Schwalbe, 2006)
Route of medication administration
(Lacro et al., 2002)
Use of oral medication (vs. depot
ones) (Lacro et al., 2002)
DRUG EFFECTIVENESS
Drug ineffectiveness, objective, or perceived (Oehl et al.,
2000; Vik et al., 2004; Munro et al., 2007P; Charach and
Gajaria, 2008P; Costello et al., 2008P; Brandes et al., 2009)
Relief of symptoms (Munro et al., 2007P;
Weiner et al., 2008)
Objective drug effectiveness (Yeung and
White, 2005; Mills et al., 2006; Costello
et al., 2008)
DURATION OF THE TREATMENT
Longer duration of treatment (Vermeire et al., 2001; Wetzels
et al., 2004; Munro et al., 2007P; Vreeman et al., 2008;
Reisner et al., 2009)
Shorter duration of treatment
(Hirsch-Moverman et al., 2008)
Duration of treatment (Ruddy et al.,
2009)
(Continued)
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Table 6 | Continued
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
DRUG TYPE
Drug type (olanzapine vs. risperidon) (Santarlasci and
Messori, 2003P)
Higher antipsychotic dose (Lacro et al., 2002)
Drug class (aRB vs. ACEi, BBs, CCBs,
diuretics) (Bramlage and Hasford, 2009P)
Drug type (fluoxetine, nortriptiline, or
imipramine, vs. other antidepressants)
(Pampallona et al., 2002), (fluoxetine vs.
others) (Pampallona et al., 2002; Lanouette
et al., 2009P)
Boosted protease inhibitors (vs. standard
therapy) (Ramos, 2009)
Greater methadone doses (Bao et al.,
2009P)
Class of medication (Lacro et al.,
2002; Julius et al., 2009)
Dose of prednisone (Jindal et al.,
2003)
Type of treatment program (in TB)
(Munro et al., 2007)
WELL ORGANISED TREATMENT
Receiving care in structured settings (e.g.,
DOT) (Malta et al., 2008)
Treatment at medical center (Charach and
Gajaria, 2008P)
Well-structured treatment plan (Oehl et al.,
2000)
Psychotherapy (along with psychotropic
medication) (Lanouette et al., 2009)
Medication supervision status (Lacro
et al., 2002)
Having a case manager (Lacro et al.,
2002)
Being aware of monitoring (Wetzels
et al., 2004)
Abbreviations: ACEi, angiotensin-converting-enzyme inhibitors; aRB, angiotensin II receptor antagonists; BBs, beta-blockers; CCBs, calcium channel blockers; DOT,
directly observed therapy; P , determinant of persistence.
Karamanidou et al., 2008; Malta et al., 2008; Reisner et al., 2009;
Schmid et al., 2009).
Only few determinants of persistence were identified. Socio-
economic factors with a negative impact on persistence included
high costs of drugs and treatment (Gold et al., 2006; Munro
et al., 2007; Costello et al., 2008), poverty (Costello et al., 2008),
lower socioeconomic status (Charach and Gajaria, 2008), or
inadequate medical/prescription coverage (Charach and Gajaria,
2008; Costello et al., 2008). Several healthcare system-related
factors also had a negative effect on persistence, such as lack
of providers/caregiver availability (Charach and Gajaria, 2008),
poor healthcare provider-patient relationship (Charach and
Gajaria, 2008), or poor follow-up by providers (Gold et al.,
2006). Asymptomatic nature of disease (Gold et al., 2006), as
well as clinical improvement, disappearance of symptoms, feel-
ing better/cured (Oehl et al., 2000; Munro et al., 2007), the
presence of adverse effects (Gold et al., 2006; Charach and
Gajaria, 2008; Costello et al., 2008; Brandes et al., 2009) and
complexity of the regimen (Gold et al., 2006; Munro et al.,
2007) all decreased patient motivation to persist with treat-
ment, as did high dosing frequency (Charach and Gajaria,
2008), doses during the day (Charach and Gajaria, 2008),
and finally, drug ineffectiveness, objective or perceived (Munro
et al., 2007; Charach and Gajaria, 2008; Costello et al., 2008).
This findings are of special interest, as longer persistence is
a primary goal for adherence-enhancing interventions. On the
other hand, it is noteworthy that the vast majority of persis-
tence determinants were also implementation determinants (see
Tables 3–7).
Our findings are consistent with those of the other authors
(Vermeire et al., 2001; DiMatteo, 2004b). However, the strength
of this study is the rigorous methodology that we employed to
classify literature search findings. A predefined set of criteria,
and the use of well-defined terminology to describe the devi-
ation of patients from prescribed treatment allowed a cohesive
matrix of factors to be built that were determinants of either
adherence or non-adherence. Bearing in mind that at least 200
factors have so far been suggested to play some role in deter-
mining adherence (Vermeire et al., 2001), the approach adopted
in our study seems to move our understanding of adherence to
medication forward. The clear distinction between implementa-
tion of the regimen (daily drug-taking) and persistence (continuity
of treatment) allows the first, to the best of our knowledge,
clear distinction of the determinants of these two components
of adherence to medication to be made, thus providing a more
detailed insight into the role of some determinants of the adher-
ence process, compared with previous approaches (e.g., theWHO
5 dimensions).
Our analysis provides clear evidence that medication non-
adherence is affected by multiple determinants, belonging to
several different fields. Many of these factors are not modifiable,
and none of them is a sole predictor of adherence. Moreover,
some of these factors change with time and can appear at times
either to be a cause, or a consequence, of patient non-adherence.
Nevertheless, non-adherence should not be perceived as patients’
fault only. To the contrary, social factors (such as social support,
economic factors, etc.), healthcare-related factors (e.g., barriers
to healthcare, and quality of provider-patient communication),
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Table 7 | Patient-related factors affecting adherence.
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
AGE
Younger age (Fogarty et al., 2002; Jindal et al., 2003; Nosé
et al., 2003; Van Der Wal et al., 2005; Chia et al., 2006;
Karamanidou et al., 2008; Julius et al., 2009; Lanouette et al.,
2009; Ruddy et al., 2009; Schmid et al., 2009)
Older children (vs. younger ones) (Weiner et al., 2008)
Age - older and younger age groups (vs. adults) (Munro et al.,
2007)
Very old age (older than 85 years) (Ruddy et al., 2009)
Younger females (vs. older ones) (Oehl
et al., 2000)
Age (Oehl et al., 2000; Vermeire et al.,
2001; Lacro et al., 2002; DiMatteo,
2004b; Vik et al., 2004; Olthoff et al.,
2005; Hodari et al., 2006;
Hirsch-Moverman et al., 2008; Reisner
et al., 2009; Ruddy et al., 2009)
GENDER
Male gender (Oehl et al., 2000; Pampallona et al., 2002; Nosé
et al., 2003; Olthoff et al., 2005; Chia et al., 2006; Munro
et al., 2007; Julius et al., 2009; Schmid et al., 2009)
Male gender (Jindal et al., 2003; Charach
and Gajaria, 2008P)
Gender (Vermeire et al., 2001; Fogarty
et al., 2002; Lacro et al., 2002; DiMatteo,
2004b; Vik et al., 2004; Van Der Wal
et al., 2005; Charach and Gajaria, 2008P;
Hirsch-Moverman et al., 2008;
Karamanidou et al., 2008; Broekmans
et al., 2009; Lanouette et al., 2009;
Reisner et al., 2009)
MARITAL STATUS
Single or divorced (vs. married) (Jindal et al., 2003; Julius
et al., 2009)
Being married (in psychosis) (Nosé et al., 2003)
Being married (Pampallona et al., 2002;
DiMatteo, 2004a; Hodari et al., 2006;
Lanouette et al., 2009)
Living with someone (vs. living alone)
(DiMatteo, 2004a)
Living alone/being single (in psychosis)
(Nosé et al., 2003)
Marital status (Vermeire et al., 2001;
Lacro et al., 2002; Vik et al., 2004;
Karamanidou et al., 2008)
Orphan status (Vreeman et al., 2008)
EDUCATION
Illiteracy (Munro et al., 2007)
Having repeated a grade in school (in HIV-infected youth)
(Reisner et al., 2009)
Education (Pampallona et al., 2002; Nosé
et al., 2003; DiMatteo, 2004b; Munro
et al., 2007; Hirsch-Moverman et al., 2008;
Julius et al., 2009; Schmid et al., 2009)
Being in school (vs. not being, in
HIV-infected youth) (Reisner et al., 2009)
High IQ (Pampallona et al., 2002)
Education (Lacro et al., 2002; Vik et al.,
2004; Olthoff et al., 2005; Van Der Wal
et al., 2005; Karamanidou et al., 2008;
Broekmans et al., 2009; Lanouette et al.,
2009)
ETHNICITY
Latinos (vs. Euro-Americans) (Lanouette et al., 2009)
Hispanic patients (in the US, in TB) (Munro et al., 2007)
Monolingual Spanish speakers (Lanouette et al., 2009)
Non-white women (Ruddy et al., 2009)
Caucasian race (Jindal et al., 2003;
Charach and Gajaria, 2008P)
U.S. born (Jindal et al., 2003)
Ethnicity (Lacro et al., 2002; Vik et al.,
2004; Van Der Wal et al., 2005;
Hirsch-Moverman et al., 2008;
Karamanidou et al., 2008; Reisner et al.,
2009; Schmid et al., 2009)
Place of birth (Hirsch-Moverman et al.,
2008)
HOUSING
Unstable housing (Hirsch-Moverman et al., 2008; Julius et al.,
2009; Reisner et al., 2009)
Homelessness (Mills et al., 2006)
Residentially mobile (Munro et al., 2007)
Being away from home (Mills et al., 2006; Karamanidou et al.,
2008; Vreeman et al., 2008; Schmid et al., 2009)
Structured environment away from home
(Munro et al., 2007)
Homelessness (Munro et al., 2007;
Hirsch-Moverman et al., 2008)
Living arrangements (Lacro et al., 2002;
Vik et al., 2004; Lanouette et al., 2009)
COGNITIVE FUNCTION
Cognitive impairment, low attention and working memory
(Fogarty et al., 2002; Nosé et al., 2003; Lovejoy and Suhr,
2009; Schmid et al., 2009)
Neurocognitive impairment (Lacro et al.,
2002; Lovejoy and Suhr, 2009)
Verbal fluency (Lovejoy and Suhr, 2009)
(Continued)
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Table 7 | Continued
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
FORGETFULNESS AND REMINDERS
Forgetting (Fogarty et al., 2002; Vik et al., 2004; Mills et al.,
2006; Schmid et al., 2009; Weiner et al., 2008)
Sleeping through a dose (Mills et al., 2006)
Making use of reminders (Mills et al.,
2006; Munro et al., 2007)
Using friends and family as reminders
(Mills et al., 2006)
Having a routine in which taking drugs
could be easily incorporated (Mills et al.,
2006)
KNOWLEDGE
Lack of comprehension of disease and treatment (Vermeire
et al., 2001; Olthoff et al., 2005; Gold et al., 2006P; Lewiecki,
2007; Charach and Gajaria, 2008P; Karamanidou et al., 2008;
Vreeman et al., 2008)
Misunderstanding of the prescription and treatment
instructions, and the consequences of non-adherence (Vik
et al., 2004; Mills et al., 2006; Munro et al., 2007; Vreeman
et al., 2008)
Misconceptions reported from the media, lay press, family or
friends, about a medication (Hodari et al., 2006)
Obtaining helpful breast cancer information from books or
magazines (in breast cancer) (Ruddy et al., 2009)
Situational operational knowledge (Jindal
et al., 2003; Mills et al., 2006)
Understanding the need for strict
adherence (Mills et al., 2006)
HEALTH BELIEFS
Denial of diagnosis (Vermeire et al., 2001; Munro et al., 2007)
Unrealistic expectations concerning the medication’s
benefit/risk ratio (Oehl et al., 2000)
Negative patients’ beliefs about the efficacy of treatment
(Mills et al., 2006; Munro et al., 2007; Malta et al., 2008;
Weiner et al., 2008; Reisner et al., 2009)
Negative attitude toward or subjective response to
medication (Lacro et al., 2002)
Thinking that the treatment could make the patients ill
(Munro et al., 2007)
Belief that taking medication together with concurrent
western or traditional medicines may have negative
consequences (in TB) (Munro et al., 2007)
Belief that pregnancy would increase intolerance to drugs
and make TB drugs ineffective (Munro et al., 2007)
Concerns that the treatment would affect immigration status,
and lead to disclosure of illegal immigrant
status/incarceration (in TB) (Munro et al., 2007)
Having doubts, or not being able to accept HIV status (Mills
et al., 2006)
Unresolved concerns about time between taking the drug
and its effect (Vermeire et al., 2001)
Being suspicious of treatment/medical establishment (Mills
et al., 2006)
Interpreting DOT as distrust (Munro et al., 2007)
“Being tired” of taking medications (Munro et al., 2007P)
Feeling that treatment is a reminder of HIV status (Mills
et al., 2006)
Perceived excessive medication use (Vik et al., 2004)
Feeling persecuted or poisoned (Oehl et al., 2000)
Lack of interest in treatment (Munro et al., 2007)
Wanting to be free of medications or preferring a natural
approach (Mills et al., 2006)
Belief in the diagnosis (Vermeire et al.,
2001)
Belief in a particular set of health
recommendations (Vermeire et al., 2001)
Belief in self-efficacy for taking medication
(Chia et al., 2006)
Self-confidence to maintain health status
(Van Der Wal et al., 2005)
Fewer concerns about drugs, belief that
medication is safe (Chia et al., 2006;
Charach and Gajaria, 2008P)
Belief that asthma is not caused by the
external factors (Chia et al., 2006)
Lower belief in natural products and home
remedies (Chia et al., 2006)
Beliefs of control over one’s health (Chia
et al., 2006)
Feeling of empowerment (Brandes et al.,
2009)
Lower control beliefs about cancer-related
pain (Chia et al., 2006)
Perceived benefits of adherence (Chia
et al., 2006; Munro et al., 2007; Costello
et al., 2008; Hirsch-Moverman et al., 2008;
Karamanidou et al., 2008)
Desire to avoid burdening family members
(Costello et al., 2008)
More motivation (Lanouette et al., 2009)
Belief that they are vulnerable or
susceptible to the disease or its
consequences (Vermeire et al., 2001)
Worrying about the disease (Weiner et al.,
2008)
HIV disease attitudes (Fogarty et al.,
2002)
Feeling invulnerable to the
consequences of HIV (Reisner et al.,
2009)
(Continued)
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Table 7 | Continued
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
Wanting to be in control (Mills et al., 2006)
Prioritizing work over taking treatment (Munro et al., 2007)
Perceived the necessity of treatment (Chia
et al., 2006; Hirsch-Moverman et al., 2008)
Regarding drugs as vital (as opposed to
important) (Olthoff et al., 2005)
Felt less burdened by taking the
medication (Chia et al., 2006)
Fear of experiencing relapses and future
disability (Costello et al., 2008)
PSYCHOLOGICAL PROFILE
Personality: low conscientiousness, high cynical hostility
(Karamanidou et al., 2008)
Pessimistic ways of coping (Weiner et al., 2008)
Withdrawal coping style, or self-destructive escape coping
style (Reisner et al., 2009)
Poor insight (Lacro et al., 2002)
Lack of self-worth (Mills et al., 2006)
Oppositional behaviours (Weiner et al., 2008)
Laziness/lack of care (Munro et al., 2007)
Being too distracted or busy (Mills et al., 2006)
Accepting the HIV-seropositivity (Mills
et al., 2006)
Coping psychologically with HIV diagnosis
(Munro et al., 2007)
Optimistic ways of coping (Weiner et al.,
2008)
Hope (Costello et al., 2008)
Insight (Nosé et al., 2003)
Higher self-efficacy (Jindal et al., 2003;
Costello et al., 2008; Reisner et al., 2009)
Higher levels of life satisfaction (Reisner
et al., 2009)
Internal locus of control (Schmid et al.,
2009)
Self-esteem (Mills et al., 2006; Costello
et al., 2008)
Lower levels of psychologic distress
(Reisner et al., 2009)
Personal control of the disease and
therapy (Costello et al., 2008; Weiner
et al., 2008)
Higher level of self-care agency score
(Jindal et al., 2003)
Living for someone, especially, children
(Mills et al., 2006)
Rewarding oneself after injections
(Costello et al., 2008)
Coping style (Karamanidou et al., 2008)
Emotional overinvolvement (Lanouette
et al., 2009)
Warmth (Lanouette et al., 2009)
More insight (Lanouette et al., 2009)
Criticism (Lanouette et al., 2009)
Less busy lifestyle (Chia et al., 2006)
Problems with role functioning
(Lanouette et al., 2009)
COMORBIDITIES AND PATIENT HISTORY
Having other concurrent illnesses affecting adherence (Mills
et al., 2006)
Non-adherence in the past (Lacro et al., 2002; Nosé et al.,
2003)
Previous treatment failure (Hodari et al., 2006)
Concurrent diseases or illnesses, including malnutrition (Mills
et al., 2006)
Psychiatric illness, e.g., anxiety/depression (Jindal et al.,
2003; Nosé et al., 2003; Hodari et al., 2006; Mills et al., 2006;
Munro et al., 2007; Karamanidou et al., 2008; Malta et al.,
2008; Reisner et al., 2009; Schmid et al., 2009)
Prior suicide attempt (Reisner et al., 2009)
Concomitant medication use (in latent TB) (Hirsch-Moverman
et al., 2008)
Recent hospitalization (Hirsch-Moverman et al., 2008)
Long hospital stay (Nosé et al., 2003)
Higher number of transplants and rejection episodes (Jindal
et al., 2003)
Less chronic co-morbidities (Van Der Wal
et al., 2005)
More severe comorbid conditions
(Charach and Gajaria, 2008)P
No previous use of disease modifying
therapies (in MS) (Costello et al., 2008)
Previous psychiatric contacts (in patients
with psychosis (Nosé et al., 2003)
Previous use of antidepressants (in
depression) (Pampallona et al., 2002)
Witnessing the consequences of not
following medical advice in relatives with
other diseases (Costello et al., 2008)
Prior history of treatment with stimulants
(in ADHD) (Charach and Gajaria, 2008)P
Current psychiatric treatment (in
depression) (Pampallona et al., 2002)
Being less likely to have bartered sex
Number of medical conditions (Chia
et al., 2006)
Adherence to other parts of an inpatient
treatment program (Lacro et al., 2002)
Presence of mood symptoms (or
diagnosis of schizoaffective or bipolar
disorder) (Lacro et al., 2002)
Anxiety (DiMatteo et al., 2007)
Concurrent methadone treatment (in
latent TB infection) (Hirsch-Moverman
et al., 2008)
Total number of therapists in lifetime
(Lanouette et al., 2009)
Number of medications prescribed for
another condition (Olthoff et al., 2005)
Diabetes, as a comorbidity (Karamanidou
et al., 2008)
Dialysis compliance (Jindal et al., 2003)
(Continued)
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Table 7 | Continued
Factors having
Negative effect on adherence Positive effect on adherence Neutral effect on adherence
Both eye blindness (Olthoff et al., 2005)
Impaired motor functioning (Lovejoy and Suhr, 2009)
History of infection (in patients after kidney transplantation)
(Jindal et al., 2003)
No history of diabetes (Jindal et al., 2003)
Sexual abuse under age of 12 years (Reisner et al., 2009)
Recent incarceration (Malta et al., 2008)
Receiving standard primary tumour therapy (in tamoxifen use
in breast cancer) (Ruddy et al., 2009P)
during the lifetime (in HIV-infected youth)
(Reisner et al., 2009)
Being less likely to have had a sexually
transmitted disease since learning their
serostatus (in HIV-infected youth) (Reisner
et al., 2009)
Using condoms with recent sex partners
(in HIV-infected youth) (Reisner et al.,
2009)
Diagnosis of asthma or COPD (in HF
patients) (Van Der Wal et al., 2005)
Lack of relapse (in depression)
(Pampallona et al., 2002)
Recent exposure to TB (Hirsch-Moverman
et al., 2008)
Previous readmission for all causes (in HF)
(Van Der Wal et al., 2005)
Previous readmission for HF (in HF) (Van
Der Wal et al., 2005)
Type of the dialysis (Karamanidou et al.,
2008)
Patient’s transplant history (Kahana
et al., 2008; Karamanidou et al., 2008)
Donor/graft source (Jindal et al., 2003;
Kahana et al., 2008)
Treated rejection episodes (Jindal et al.,
2003)
ALCOHOL OR SUBSTANCE ABUSE
Substance abuse (Oehl et al., 2000; Lacro et al., 2002; Nosé
et al., 2003; Mills et al., 2006; Munro et al., 2007; Malta
et al., 2008; Lanouette et al., 2009)
Injection drugs use (vs. non-injection ones) (Malta et al.,
2008)
Younger age of first marijuana use (Reisner et al., 2009)
Alcohol abuse (Oehl et al., 2000)
Smoking (Hodari et al., 2006; Schmid et al., 2009)
Less recent drug use in the previous
3 months (in HIV-infected youth) (Reisner
et al., 2009)
Medication taking priority over substance
use (Mills et al., 2006)
Drug addiction treatment, especially
substitution therapy (for HIV treatment in
drug users) (Malta et al., 2008)
Drinking less, or non-drinking (Hodari
et al., 2006; Reisner et al., 2009)
Injective drug using (Munro et al., 2007)
PATIENT-RELATED BARRIERS TO COMPLIANCE
Transportation difficulties (Mills et al., 2006; Schmid et al.,
2009)
Abbreviations: HF, heart failure; MS, multiple sclerosis; TB, tuberculosis; P , determinant of persistence.
condition characteristics, as well as therapy-related factors (such
as patient friendliness of the therapy) play an important role in
defining adherence.
Consequently, multifaceted interventions may be the most
effective answer toward unsatisfactory adherence, and its
consequences. In their review of reviews of effectiveness of
adherence-enhancing interventions, van Dulmen et al. found
effective interventions in each of four groups: technical, behav-
ioral, educational and multi-faceted or complex interventions
(van Dulmen et al., 2007). In their Cochrane review, Haynes et al.
(Haynes et al., 2008) observed that most of the interventions that
were effective for long-term care were complex, targeting multiple
adherence determinants. We believe that evidence accumulated in
this study may help in designing such effective interventions, and
thus, be applied in both clinical practice and public health.
Bearing in mind the number of identified determinants
and their inconsistent effect on adherence, prediction of
non-adherence of individual patients is difficult if not impossible.
In particular, the inconsistent effect of demographic variables on
patient adherence explains partly why healthcare providers are
ineffective in predicting adherence in their patients (Okeke et al.,
2008). In fact, their prediction rate is no better than a coin toss
(Mushlin and Appel, 1977). Neither age, gender, marital status,
nor education proved to fully explain the variance in patient
adherence across conditions and settings. Therefore, in order
to reveal cases of non-adherence, validated tools (e.g., Morisky,
or MARS questionnaires), and objective assessment methods
(electronic monitoring widely accepted as a gold standard) are
strongly advisable (Osterberg and Blaschke, 2005). In daily prac-
tice, relevant databases, such as electronic health records, and
pharmacy fill records, may be effectively used for screening for
non-adherence (Carroll et al., 2011; Grimes et al., 2013). On the
other hand, adherence-enhancing interventions are worth con-
sidering to implement in daily clinical practice, to be used on a
regular basis for every individual patients.
Finally, another strength of this systematic literature review
is the identification of existing gaps in our understanding of
adherence. Of note is that despite the broad inclusion crite-
ria adopted for this search, no systematic review was identi-
fied which provides determinants of adherence with short-term
Frontiers in Pharmacology | Pharmaceutical Medicine and Outcomes Research July 2013 | Volume 4 | Article 91 | 14
Kardas et al. Determinants of patient adherence
treatments. Considering the high prevalence of non-adherence to
short-term therapies, and especially, to antibiotics (Kardas et al.,
2005; Vrijens et al., 2005), our findings identify this field as an
important area for future research.
The major limitation of this study was connected with the data
available within the source publications that were used for this
review. Most did not provide any precise definition of adherence,
nor any numeric values to describe the effect of the particular
determinants on adherence (e.g., the effect size), thus making
secondary analysis not manageable. The poor designs of many
original studies on determinants of non-adherence could affect
the conclusions of identified reviews, and indirectly, the results of
this review.
The “review of reviews” methodology we employed in the
present study proved to be a valuable tool for gathering relevant
studies. However, despite the fact that the source reviews adopted
different focuses, the certain level of overlap in primary studies
they reviewed cannot be ruled out. Nevertheless, as the aim of the
study was to build a comprehensive list of determinants, and not
to perform a meta-analysis, this possible overlap was not a source
of additional bias.
Finally, although our selection of the databases searched
was only arbitral, it did correspond with the major goal,
i.e., identification of publications describing determinants of
adherence to medication. According to our experience, and
knowledge of similar publications, broadening the scope
of the databases included would not add much to the
findings.
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